irampanel: structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 3038472 |
| CHEMBL ID | 29741 |
| SCHEMBL ID | 678128 |
| MeSH ID | M0305540 |
| Synonym |
|---|
| biir-561cl |
| 5-(o-(2-(dimethylamino)ethoxy)phenyl)-3-phenyl-1,2,4-oxadiazole |
| 206260-33-5 |
| unii-r2gzd7lmyx |
| irampanel [inn] |
| 5-(o-(2-(dimethylamino)ethoxy)phenyl)-3-phenyl-1,2,4-oxadiazole. |
| dimethyl-(2-(2-(3-phenyl-(1,2,4)oxadiazol-5-yl)phenoxy)ethyl)amine hydrochloride |
| r2gzd7lmyx , |
| irampanel |
| biir-561 cl |
| CHEMBL29741 |
| biir 561 |
| biir-561 |
| n,n-dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine |
| SCHEMBL678128 |
| irampanel [who-dd] |
| 5-{2-[2-(n,n-dimethylamino)ethyl]oxy-phenyl}-3-phenyl-1,2,4-oxadiazole |
| QZULPCPLWGCGSL-UHFFFAOYSA-N |
| DTXSID30174647 |
| ethanamine,n,n-dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]- |
| Q19597602 |
| dimethyl({2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethyl})amine |
| EN300-26482298 |
| AKOS040748592 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID496840 | Anticonvulsant activity in ip dosed DBA2 mouse assessed as inhibition of sound-induced clonic seizures | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 ISSN: 1520-4804 | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside. |
| AID496872 | Protection against AMPA-induced lethality in mouse | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 ISSN: 1520-4804 | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside. |
| AID197266 | In vivo anticonvulsant activity to prevent seizures from maximum electroshock (MES) in rat hippocampal slices | 2001 | Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2 ISSN: 0022-2623 | Medicinal chemistry of neuronal voltage-gated sodium channel blockers. |
| AID496833 | Antagonist activity at AMPA receptor in rat cortical membrane assessed as inhibition of AMPA-induced membrane current | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 ISSN: 1520-4804 | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (37.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (62.50%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | non-proteinogenic alpha-amino acid | 1999 | 2001 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 | ||
| gyki 52466 | benzodiazepine | 1999 | 2001 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 | ||
| mexiletine | aromatic ether; primary amino compound | anti-arrhythmia drug | 1999 | 2001 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 | |
| quinoxalines | mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 2 | 0 | 0 | ||
| glutamic acid | glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical | 1999 | 2000 | 24.5 | low | 0 | 0 | 2 | 0 | 0 | 0 | |
| gyki 53655 | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |||
| 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline | naphthalenes; sulfonic acid derivative | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 2 | 0 | 0 | ||
| oxadiazoles | 1999 | 2002 | 23.2 | medium | 0 | 0 | 2 | 4 | 0 | 0 | |||
| veratridine | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALS - Amyotrophic Lateral Sclerosis | 0 | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Amyotrophic Lateral Sclerosis | 0 | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Anterior Circulation Transient Ischemic Attack | 0 | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| Apoplexy | 0 | 2001 | 2002 | 22.3 | medium | 0 | 0 | 0 | 3 | 0 | 0 | |
| Aura | 0 | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Brain Ischemia | 0 | 2001 | 2002 | 22.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 | |
| Cardiac Death | 0 | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Cerebral Ischemia | 0 | 2001 | 2002 | 22.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 | |
| Disease Models, Animal | 0 | 2001 | 2002 | 22.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 | |
| Epilepsy | 0 | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Ischemic Attack, Transient | 0 | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| Stroke | 0 | 2001 | 2002 | 22.3 | medium | 0 | 0 | 0 | 3 | 0 | 0 |